Mark Day

Mark Day is an Adjunct Professor affiliated with Yale University's School of Medicine. He currently serves as Senior Director of Corporate Development at Alexion Pharmaceuticals, focusing on ultra-rare diseases. His career includes roles at BMS, Abbott Labs, Psychogenics, Wyeth, GSK, and the University of Edinburgh. He holds a PhD and BS from Cardiff University (2000 and 1997).

His research centers on translational neuroimaging, pharmacological biomarkers, and drug discovery for neurological and psychiatric conditions. Key contributions include developing pharmacological MRI (phMRI) techniques to assess drug efficacy and target engagement in preclinical models. Over 50 peer-reviewed articles highlight his work on muscarinic receptors, NMDA antagonists, and biomarker validation.

His publications span 2003–2012, emphasizing neuroimaging applications in drug development. Notable studies include ketamine-challenge models and muscarinic receptor modulation in awake rats. His work bridges academia and industry, advancing tools for early-phase clinical trials in schizophrenia and pain management.